Director of the ART ARNm Inserm and professor of molecular and cellular biology Chantal Pichon poses next to a bioreactor at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

Director of the ART ARNm Inserm and professor of molecular and cellular biology Chantal Pichon poses next to a bioreactor at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

Teacher-researcher Maryvonne Ardourel points towards a pancreatic cancer cell on a micrograph displayed on a screen at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

A researcher carries out the assembly of a transcription reaction that generates messenger RNA from synthetic DNA at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

Director of the ART ARNm Inserm and professor of molecular and cellular biology Chantal Pichon poses next to a bioreactor at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

France's junior Minister in charge of artificial intelligence Anne Le Henanff tours a stands displaying cyber security cases during the European Cyber Week in Rennes, western France, on November 20, 2025. (Photo by Damien MEYER / AFP) (Photo by DAMIEN MEYER/AFP via Getty Images)

France's junior Minister in charge of artificial intelligence Anne Le Henanff speaks to media as she attends the European Cyber Week in Rennes, western France, on November 20, 2025. (Photo by Damien MEYER / AFP) (Photo by DAMIEN MEYER/AFP via Getty Images)

France's junior Minister in charge of artificial intelligence Anne Le Henanff tours a stands displaying cyber security cases during the European Cyber Week in Rennes, western France, on November 20, 2025. (Photo by Damien MEYER / AFP) (Photo by DAMIEN MEYER/AFP via Getty Images)